<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727477</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-1803</org_study_id>
    <nct_id>NCT03727477</nct_id>
  </id_info>
  <brief_title>Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib</brief_title>
  <acronym>LORLATU</acronym>
  <official_title>Efficacy of Treatment Sequences in Patients With ALK and ROS-1 Positive Non-small Cell Lung Cancer Who Received Lorlatinib as Part of the French Expanded Access Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate progression-free survival, overall survival, best response and
      duration of treatment in patients with advanced ALK- and ROS1-positive non-small cell lung
      cancer who received lorlatinib as part of the French expanded access program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IFCT-1803 LORLATU study will evaluate progression-free survival, overall survival, best
      response and duration of treatment in patients with advanced ALK- and ROS1-positive non-small
      cell lung cancer who received lorlatinib (PF-06463922) as part of the French expanded access
      program. Those outcomes will be correlated to clinical, pathological, and radiological
      characteristics of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>October 2015 - December 2019</time_frame>
    <description>time from first dose of treatment to first occurrence of disease progression or death from any cause during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
    <time_frame>October 2015 - December 2019</time_frame>
    <description>best response recorded from the start of treatment until disease progression or start of further anti-cancer treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment</measure>
    <time_frame>October 2015 - December 2019</time_frame>
    <description>time from first dose of treatment to discontinuation of treatment or death from any cause during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of tumor progression</measure>
    <time_frame>October 2015 - December 2019</time_frame>
    <description>site of disease progression after each line of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for treatment discontinuation</measure>
    <time_frame>October 2015 - December 2019</time_frame>
    <description>this may be disease progression, toxicity, death, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment beyond progression</measure>
    <time_frame>October 2015 - December 2019</time_frame>
    <description>time between first occurrence of disease progression and discontinuation the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Nervous System (CNS) best response</measure>
    <time_frame>October 2015 - December 2019</time_frame>
    <description>in patients with CNS measurable lesion, best response on CNS locations recorded from the start of treatment until disease progression or start of further anti-cancer treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Nervous System (CNS) Progression free survival</measure>
    <time_frame>October 2015 - December 2019</time_frame>
    <description>time from first dose of treatment to first occurrence of disease progression in the CNS or death from any cause during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>October 2015 - December 2019</time_frame>
    <description>is defined as the time from the first dose of treatment dose and death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>October 2015 - December 2019</time_frame>
    <description>complications of lorlatinib therapy will be recorded</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <condition>ALK Gene Rearrangement Positive</condition>
  <condition>ROS-1 Gene Rearrangement Positive</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically or cytologically confirmed locally advanced or metastatic
        NSCLC who received at least one week of treatment with lorlatinib as part of the French
        Expanded Access Program (ATU program).

        Selection period would start at October 2015 (e.g.,initiation of lorlatinib treatment)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed locally advanced or metastatic
             NSCLC (Stage IIIB or IV accordingly to American Joint Committee on Cancer [AJCC]
             classification) at time of lorlatinib initiation

          -  Patients who received at least one week of treatment with lorlatinib as part of the
             French Expanded Access Program (ATU program); ATU was granted due to their inability
             to meet eligibility criteria for on-going recruiting trials, inability to participate
             in other clinical trials (e.g., poor performance status, lack of geographic
             proximity), or because other medical interventions are not considered appropriate or
             acceptable.

        Exclusion Criteria:

          -  Patients enrolled in a lorlatinib clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Girard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franck Morin, MSc</last_name>
    <phone>0033156811045</phone>
    <email>contact@ifct.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascale Missy, PhD</last_name>
    <phone>0033156811045</phone>
    <email>contact@ifct.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aix-en-Provence - CH</name>
      <address>
        <city>Aix-en-Provence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie MARTINEZ, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angers - CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José HUREAUX, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avignon - CH</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas CLOAREC, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux - Polyclinique</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigolène GALLAND-GIRODET, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brest - Morvan CHU</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud DESCOURT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cahors - CH</name>
      <address>
        <city>Cahors</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia BARRE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chartres-CH</name>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong RABUT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand - CHU</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick MERLE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colmar - CH</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel MOREAU, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Créteil - CHI</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle MONNET, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Roche-Sur-Yon - CH</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie MARCQ, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Libourne - CH</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent PORTEL, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lorient - CHBS</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Régine LAMY, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon - CRLCC</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie AVRILLON, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille - CRLCC</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne MADROSZYK, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montpellier - ICM</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine BECHT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mulhouse - GHRMSA</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier DEBIEUVRE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris - Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas GIRARD, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris - Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludovic DOUCET, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris - Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques CADRANEL, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon - URCOT</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaël DURUISSEAUX, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reims - CHU</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime DEWOLF, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Nazaire - Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry CHATELLIER, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Etienne - CHU</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire TISSOT FILIPPELLO, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulouse - CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien MAZIERES, Pr</last_name>
    </contact>
    <contact_backup>
      <email>contact@ifct.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tours - CHU</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric PICHON</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valenciennes - Clinique</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GEY, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vandoeuvre-lès-Nancy - CRLCC</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle CLEMENT-DUCHENE</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Villejuif - Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin BESSE, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lorlatinib</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

